enVVeno Medical Corp Research and Development Expense
enVVeno Medical Corp (NVNO) reported Research and Development Expense of $2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- enVVeno Medical Corp research and development expense for the quarter ending 2026-06-30 was $2.08M, a 28.19% decline year-over-year.
- enVVeno Medical Corp research and development expense for the quarter ending 2026-03-31 was $2.11M, a 17.44% decline year-over-year.
- enVVeno Medical Corp research and development expense for the quarter ending 2025-12-31 was $1.95M, a 44.55% decline year-over-year.
- enVVeno Medical Corp research and development expense for the quarter ending 2025-09-30 was $2.58M, a 9.58% decline year-over-year.
- enVVeno Medical Corp research and development expense for fiscal 2025 was $9.98M, a 18.52% decline from fiscal 2024.
- enVVeno Medical Corp research and development expense for fiscal 2024 was $12.25M, a 9.82% decline from fiscal 2023.
- enVVeno Medical Corp research and development expense for fiscal 2023 was $13.58M, a 37.01% increase from fiscal 2022.
- enVVeno Medical Corp research and development expense for fiscal 2022 was $9.91M, a 73.08% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-07-30 | $4.19M 10-Q · filed 2026-07-30 | $6.13M derived: sum of 3 quarters · filed 2026-07-30 | $8.72M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $2.11M 10-Q · filed 2026-05-06 | $4.06M derived: sum of 2 quarters · filed 2026-05-06 | $6.64M derived: sum of 3 quarters · filed 2026-05-06 | $9.54M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $4.53M derived: sum of 2 quarters · filed 2026-03-26 | $7.42M derived: sum of 3 quarters · filed 2026-07-30 | $9.98M 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | $2.58M 10-Q · filed 2025-10-30 | $5.48M derived: sum of 2 quarters · filed 2026-07-30 | $8.03M 10-Q · filed 2025-10-30 | $11.55M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $2.89M 10-Q · filed 2026-07-30 | $5.45M 10-Q · filed 2026-07-30 | $8.96M derived: sum of 3 quarters · filed 2026-07-30 | $11.82M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $2.56M 10-Q · filed 2026-05-06 | $6.07M derived: sum of 2 quarters · filed 2026-05-06 | $8.93M derived: sum of 3 quarters · filed 2026-05-06 | $11.75M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $3.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $6.37M derived: sum of 2 quarters · filed 2026-03-26 | $9.20M derived: sum of 3 quarters · filed 2026-03-26 | $12.25M 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | $2.86M 10-Q · filed 2025-10-30 | $5.68M derived: sum of 2 quarters · filed 2025-10-30 | $8.74M 10-Q · filed 2025-10-30 | $11.72M derived: sum of 4 quarters · filed 2025-10-30 | ||||
| 2024-06-30 | $2.83M 10-Q · filed 2025-07-31 | $5.88M 10-Q · filed 2025-07-31 | $8.86M derived: sum of 3 quarters · filed 2025-07-31 | $11.66M derived: sum of 4 quarters · filed 2025-07-31 | ||||
| 2024-03-31 | $3.05M 10-Q · filed 2025-04-30 | $6.03M derived: sum of 2 quarters · filed 2025-04-30 | $8.83M derived: sum of 3 quarters · filed 2025-04-30 | $13.04M derived: sum of 4 quarters · filed 2025-04-30 | ||||
| 2023-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $5.78M derived: sum of 2 quarters · filed 2025-02-28 | $9.99M derived: sum of 3 quarters · filed 2025-02-28 | $13.58M 10-K · filed 2025-02-28 | ||||
| 2023-09-30 | $2.80M 10-Q · filed 2024-10-31 | $7.01M derived: sum of 2 quarters · filed 2024-10-31 | $10.60M 10-Q · filed 2024-10-31 | $13.40M derived: sum of 4 quarters · filed 2024-10-31 | ||||
| 2023-06-30 | $4.21M 10-Q · filed 2024-07-31 | $7.81M 10-Q · filed 2024-07-31 | $10.61M derived: sum of 3 quarters · filed 2024-07-31 | $13.10M derived: sum of 4 quarters · filed 2024-07-31 | ||||
| 2023-03-31 | $3.60M 10-Q · filed 2024-05-08 | $6.39M derived: sum of 2 quarters · filed 2024-05-08 | $8.88M derived: sum of 3 quarters · filed 2024-05-08 | $11.96M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $5.29M derived: sum of 2 quarters · filed 2024-02-29 | $8.36M derived: sum of 3 quarters · filed 2024-02-29 | $9.91M 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | $2.49M 10-Q · filed 2023-10-26 | $5.57M derived: sum of 2 quarters · filed 2023-10-26 | $7.12M 10-Q · filed 2023-10-26 | $8.90M derived: sum of 4 quarters · filed 2023-10-26 | ||||
| 2022-06-30 | $3.07M 10-Q · filed 2023-07-31 | $4.63M 10-Q · filed 2023-07-31 | $6.41M derived: sum of 3 quarters · filed 2023-07-31 | $7.63M derived: sum of 4 quarters · filed 2023-07-31 | ||||
| 2022-03-31 | $1.55M 10-Q · filed 2023-04-28 | $3.33M derived: sum of 2 quarters · filed 2023-04-28 | $4.56M derived: sum of 3 quarters · filed 2023-04-28 | $5.65M derived: sum of 4 quarters · filed 2023-04-28 | ||||
| 2021-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $3.01M derived: sum of 2 quarters · filed 2023-03-02 | $4.10M derived: sum of 3 quarters · filed 2023-03-02 | $5.73M 10-K · filed 2023-03-02 | $5.73M 10-K · filed 2022-03-28 | |||
| 2021-09-30 | $1.23M 10-Q · filed 2022-10-27 | $1.22M 10-Q · filed 2021-11-12 | $2.31M derived: sum of 2 quarters · filed 2022-10-27 | $3.95M 10-Q · filed 2022-10-27 | $3.95M 10-Q · filed 2021-11-12 | $6.22M derived: sum of 4 quarters · filed 2022-10-27 | ||
| 2021-06-30 | $1.09M 10-Q · filed 2022-08-03 | $1.09M 10-Q · filed 2021-08-11 | $2.72M 10-Q · filed 2022-08-03 | $2.72M 10-Q · filed 2021-08-11 | $5.00M derived: sum of 3 quarters · filed 2022-08-03 | $5.76M derived: sum of 4 quarters · filed 2022-08-03 | ||
| 2021-03-31 | $1.63M 10-Q · filed 2022-04-29 | $1.63M 10-Q · filed 2021-05-12 | $3.91M derived: sum of 2 quarters · filed 2022-04-29 | $4.67M derived: sum of 3 quarters · filed 2022-04-29 | $5.37M derived: sum of 4 quarters · filed 2022-04-29 | |||
| 2020-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $3.04M derived: sum of 2 quarters · filed 2022-03-28 | $3.74M derived: sum of 3 quarters · filed 2022-03-28 | $4.25M 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | $758.20K 10-Q · filed 2021-11-12 | $1.46M derived: sum of 2 quarters · filed 2021-11-12 | $1.97M 10-Q · filed 2021-11-12 | $2.76M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $706.17K 10-Q · filed 2021-08-11 | $1.22M 10-Q · filed 2021-08-11 | $2.00M derived: sum of 3 quarters · filed 2021-08-11 | $2.68M derived: sum of 4 quarters · filed 2021-08-11 | ||||
| 2020-03-31 | $510.62K 10-Q · filed 2021-05-12 | $1.30M derived: sum of 2 quarters · filed 2021-05-12 | $1.98M derived: sum of 3 quarters · filed 2021-05-12 | $2.40M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | $787.83K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $1.46M derived: sum of 2 quarters · filed 2021-03-31 | $1.89M derived: sum of 3 quarters · filed 2021-03-31 | $2.21M 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $676.97K 10-Q · filed 2020-11-17 | $1.11M derived: sum of 2 quarters · filed 2020-11-17 | $1.42M 10-Q · filed 2020-11-17 | $1.71M derived: sum of 4 quarters · filed 2020-11-17 | ||||
| 2019-06-30 | $428.31K 10-Q · filed 2020-08-14 | $428.31K 10-Q · filed 2019-08-05 | $741.32K 10-Q · filed 2020-08-14 | $1.03M derived: sum of 3 quarters · filed 2020-08-14 | $1.46M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | $313.01K 10-Q · filed 2020-06-08 | $606.25K derived: sum of 2 quarters · filed 2020-06-08 | $1.03M derived: sum of 3 quarters · filed 2020-06-08 | $1.31M derived: sum of 4 quarters · filed 2020-06-08 | ||||
| 2018-12-31 | $293.24K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-18 | $717.84K derived: sum of 2 quarters · filed 2020-03-18 | $998.26K derived: sum of 3 quarters · filed 2020-03-18 | $1.24M 10-K · filed 2020-03-18 | ||||
| 2018-09-30 | $424.60K 10-Q · filed 2019-10-31 | $705.01K derived: sum of 2 quarters · filed 2019-10-31 | $945.51K 10-Q · filed 2019-10-31 | $1.29M derived: sum of 4 quarters · filed 2019-10-31 | ||||
| 2018-06-30 | $280.42K 10-Q · filed 2019-08-05 | $520.91K 10-Q · filed 2019-08-05 | $870.00K derived: sum of 3 quarters · filed 2019-08-05 | $913.07K derived: sum of 4 quarters · filed 2019-08-05 | ||||
| 2018-03-31 | $240.49K 10-Q · filed 2019-05-09 | $589.58K derived: sum of 2 quarters · filed 2019-05-09 | $632.65K derived: sum of 3 quarters · filed 2019-05-09 | $817.57K derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $349.09K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $392.16K derived: sum of 2 quarters · filed 2019-03-14 | $577.08K derived: sum of 3 quarters · filed 2019-03-14 | $649.74K 10-K · filed 2019-03-14 | ||||
| 2017-09-30 | $43.07K 10-Q · filed 2018-11-07 | $227.99K derived: sum of 2 quarters · filed 2018-11-07 | $300.65K 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $184.92K 10-Q · filed 2018-08-10 | $257.58K 10-Q · filed 2018-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |